血紅素病治療藥物市場：按藥物類型、按疾病類型、按分銷管道、按地區 - 規模、份額、展望、機會分析，2023-2030 年

Hemoglobinopathy Treatment Drugs Market, By Drug Type, By Disease Type, By Distribution Channel, By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年08月01日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年血紅素病藥物的全球市場規模預計為45億美元，預測期內（2023-2030年）複合年增長率為8.4%。

報告範圍		報告詳細資料
基準年	2022	2023 年市場規模	美國：45億美元
過去的資料	2018年至2021年	預測期間	2023-2030
預測 2023-2030 年複合年增長率：	8.40%	2030年價值預測	美國：79億美元

治療血紅素疾病的藥物包括所有血紅素遺傳性疾病。這些主要分為兩組：地中海貧血綜合症和結構性血紅蛋白變異（血紅蛋白異常）。 HbS、HbE 和 HbC 是主要的結構性血紅蛋白變異。每個組都有許多子類型和複雜類型。血紅素病的臨床表現變化很大，從輕度低色素性貧血到中度血液系統疾病，再到嚴重的終生輸血依賴性貧血並伴隨多重器官受累。幹細胞移植是嚴重地中海型貧血的首選治療方法。支持治療而非治療涉及終身定期輸血並結合鐵螯合療法。用於治療鐮狀細胞疾病症狀的藥物包括止痛藥、抗生素、ACE 抑制劑和羥基尿。僅在有嚴格指徵時才進行輸血。目前，90%以上的患者存活至成年。接受最佳治療的患者預計可活 50 至 60 年。血紅蛋白病是最常見的單一發炎性疾病，也是世界主要健康問題之一，世界人口中約 7% 是血紅素病帶因者。治療血紅蛋白疾病的藥物最初分佈在地中海地區以及亞洲和非洲的大部分地區。國際移民已從這些地區蔓延到世界各地。如今，血紅素 (Hb) 異常在歐洲許多地區被列為地方病。

市場動態

主要市場參與者不斷增加的新產品推出和併購預計將推動全球血紅蛋白病藥物市場的成長。例如，2022年8月8日，美國跨國製藥和生技公司輝瑞公司（Pfizer Inc.）與美國醫療保健公司World Blood Therapeutics, Inc.宣布，輝瑞公司（Pfizer Inc.）宣布已與美國醫療保健公司World Blood Therapeutics, Inc.達成合作協議。收購 GBT 的正式協議。透過此交易，輝瑞將以每股68.50美元現金收購World Blood Therapeutics全部流通股，扣除收購的債務和現金後企業總價值約54億美元。兩家公司董事會一致批准了本次交易。

本研究的主要特點

本報告詳細分析了全球血紅蛋白病治療藥物市場，並介紹了以 2022 年為基準年的預測期（2023-2030 年）的市場規模和復合年增長率 (CAGR)。我是。
它也揭示了各個細分市場的潛在收入機會，並為該市場提供了一系列有吸引力的投資建議。
它還提供了有關市場驅動因素、限制因素、機會、新產品發布和批准、市場趨勢、區域前景、主要參與者採取的競爭策略等的重要見解。
根據公司亮點、產品組合、主要亮點、績效和策略等參數對全球血紅蛋白病藥物市場的主要參與者進行了分析。
本研究涵蓋的主要公司包括Bristol-Myers Squibb Company、GlycoMimetics Inc.、Pfizer Inc.、Anthera Pharmaceuticals Inc.、Eli Lilly and Company、Mast Therapeutics、Daiichi Sankyo Company Ltd.、Novartis International AG 和Bluebird Bio Inc . .、HemaQuest Pharmaceuticals Inc.、Emmaus Medical Inc.、Baxter International Inc.、Prolong Pharmaceuticals、Medunik USA Inc.、Sangamo Therapeutics, Inc.、Global Blood Therapeutics、Alnylam Pharmaceuticals 和 Acceleron Pharma, Inc. 將出席。
《全球血紅蛋白病藥物市場》報告面向該行業的各個利益相關者，例如投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
透過用於分析全球血紅蛋白病藥物市場的各種策略矩陣，將有助於利害關係人做出決策。

Bristol-Myers Squibb Company
GlycoMimetics Inc.
Pfizer Inc.
Anthera Pharmaceuticals Inc.
Eli Lilly and Company
Mast Therapeutics
Daiichi Sankyo Company Ltd.
Novartis International AG
Bluebird Bio Inc.
HemaQuest Pharmaceuticals Inc.
Emmaus Medical Inc.
Baxter International Inc.
Prolong Pharmaceuticals
Medunik USA Inc.
Sangamo Therapeutics, Inc.
Global Blood Therapeutics
Alnylam Pharmaceuticals
Acceleron Pharma, Inc.

第 10 章

調查方法
關於出版商

簡介目錄

Product Code: CMI4059

Global hemoglobinopathy treatment drugs market is estimated to be valued at US$ 4.5 billion in 2023 and is expected to exhibit a CAGR of 8.4% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 4.5 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	8.40%	2030 Value Projection:	US$ 7.9 Bn

Hemoglobinopathy Treatment Drugs Market - IMG1

The hemoglobinopathies encompass all genetic diseases of hemoglobin. They fall into two main groups: thalassemia syndromes and structural hemoglobin variants (abnormal hemoglobins). α and β thalassemia are the main types of thalassemia; the main structural hemoglobin variants are HbS, HbE, and HbC. There are many subtypes and combined types in each group. The highly variable clinical manifestations of the hemoglobinopathies range from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Stem-cell transplantation is the preferred treatment for severe forms of thalassemia. Supportive, rather than curative, treatment consists of periodic blood transfusions for life combined with iron chelation. Drugs to treat the symptoms of sickle-cell disease include analgesics, antibiotics, ACE inhibitors, and hydroxyurea. Blood transfusions should be given only when strictly indicated. More than 90% of patients currently survive into adulthood. Optimally treated patients have a projected life span of 50 to 60 years. With approximately 7% of the worldwide population being carriers, hemoglobinopathies are the most common monogenic diseases and one of the world's major health problems. They were originally found mainly in the Mediterranean area and large parts of Asia and Africa. International migration has spread them from those areas all over the world. In many parts of Europe today, hemoglobin (Hb) defects are classified as endemic diseases.

Market Dynamics

Increasing launches of new products and mergers and acquisitions by key market players are expected to drive the global hemoglobinopathy treatment drugs market growth. For instance, on August 8, 2022, Pfizer Inc., a U.S.-based multinational pharmaceutical and biotechnology corporation, and Global Blood Therapeutics, Inc., a U.S.-based Healthcare company, announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms of the transaction, Pfizer Inc will acquire all the outstanding shares of Global Blood Therapeutics, Inc. for US$ 68.50 per share in cash, for a total enterprise value of approximately US$ 5.4 billion, including debt and net of cash acquired. The Boards of Directors of both companies have unanimously approved the transaction.

Key features of the study:

This report provides an in-depth analysis of the global hemoglobinopathy treatment drugs market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hemoglobinopathy treatment drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Baxter International Inc., Prolong Pharmaceuticals, Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.
Global hemoglobinopathy treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemoglobinopathy treatment drugs market

Detailed Segmentation:

Global Hemoglobinopathy Treatment Drugs Market, By Drug Type:
- Analgesics
- Antibiotics
- ACE Inhibitors
- Hydroxyurea
- Others
Global Hemoglobinopathy Treatment Drugs Market, By Disease Type:
- Thalassemia
- Sickle Cell Disease
- Other Hb Variants Diseases
Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Hemoglobinopathy Treatment Drugs Market, By Region:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Bristol-Myers Squibb Company
- GlycoMimetics Inc.
- Pfizer Inc.
- Anthera Pharmaceuticals Inc.
- Eli Lilly and Company
- Mast Therapeutics
- Daiichi Sankyo Company Ltd.
- Novartis International AG
- Bluebird Bio Inc.
- HemaQuest Pharmaceuticals Inc.
- Emmaus Medical Inc.
- Baxter International Inc.
- Prolong Pharmaceuticals
- Medunik USA Inc.
- Sangamo Therapeutics, Inc.
- Global Blood Therapeutics, Inc.
- Alnylam Pharmaceuticals
- Acceleron Pharma, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Hemoglobinopathy Treatment Drugs Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Hemoglobinopathy Treatment Drugs Market, By Drug Type, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Hydroxyurea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

6. Global Hemoglobinopathy Treatment Drugs Market, By Disease Type, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Sickle Cell Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Other Hb Variants Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

7. Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

8. Global Hemoglobinopathy Treatment Drugs Market, By Region, 2018-2030, (US$ Billion)

Introduction
North America
Latin America
Europe
Asia Pacific
Middle East
Africa

9. Competitive Landscape

Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlycoMimetics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Anthera Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mast Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Daiichi Sankyo Company Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bluebird Bio Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
HemaQuest Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Emmaus Medical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Prolong Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Medunik USA Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Sangamo Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Global Blood Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
Alnylam Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Acceleron Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies